John K. Eaton
Auto-generated profile, based on publicly available information

John K. Eaton

Kojin Therapeutics

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Science
Verified
Journal Article
Closed access
PTPeter Tsvetkov
Peter Tsvetkov
SCShannon Coy
Shannon Coy
Boryana PetrovaBoryana Petrova
Boryana Petrova
MDMargaret Dreishpoon
Margaret Dreishpoon
AVAna Verma
Ana Verma
TGTodd R. Golub
Todd R. Golub
Copper is an essential cofactor for all organisms, and yet it becomes toxic if concentrations exceed a threshold maintained by evolutionarily conserved homeostatic mechanisms. How excess copper induces cell death, however, is unknown. Here, we show in human cells that copper-dependent, regulated cell death is distinct from known death mechanisms and is dependent on mitochondrial respiration. We show that copper-dependent death occurs by means of direct binding of copper to lipoylated components of the tricarboxylic acid (TCA) cycle. This results in lipoylated protein aggregation and subsequent iron-sulfur cluster protein loss, which leads to proteotoxic stress and ultimately cell death. These findings may explain the need for ancient copper homeostatic mechanisms.

5 July 2017 in Nature
Verified
Journal Article
Closed access
PDF file
VVVasanthi S. Viswanathan
Vasanthi S. Viswanathan
MRMatthew J. Ryan
Matthew J. Ryan
HDHarshil D. Dhruv
Harshil D. Dhruv
SGShubhroz Gill
Shubhroz Gill
OEOssia M. Eichhoff
Ossia M. Eichhoff
SSStuart L. Schreiber
Stuart L. Schreiber

1 November 2017 in Nature
Verified
Journal Article
Open access
PDF file
MHMatthew J. Hangauer
Matthew J. Hangauer
VVVasanthi S. Viswanathan
Vasanthi S. Viswanathan
MRMatthew J. Ryan
Matthew J. Ryan
DBDhruv Bole
Dhruv Bole
JEJohn K. Eaton
John K. Eaton
MMMichael T. McManus
Michael T. McManus
Cancer persister cells, which survive cytotoxic treatments, are shown to be sensitive to inhibition of the lipid hydroperoxidase GPX4. During cancer treatment, tumours can become drug-resistant. In addition, so-called persister cells can emerge and form a reservoir from which resistant cancer cells can originate. Persister cells are no longer sensitive to some drugs, but Michael McManus and colleagues now report that they exist in a mesenchymal state in which they are selectively sensitive to the inhibition of the lipid hydroperoxidase GPX4. Targeting GPX4 could therefore represent a new therapeutic avenue to potentially prevent drug resistance. Acquired drug resistance prevents cancer therapies from achieving stable and complete responses1. Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer ‘persister’ cells2,3,4. The persister cell pool constitutes a reservoir from which drug-resistant tumours may emerge. Targeting persister cells therefore presents a therapeutic opportunity to impede tumour relapse5. We previously found that cancer cells in a high mesenchymal therapy-resistant cell state are dependent on the lipid hydroperoxidase GPX4 for survival6. Here we show that a similar therapy-resistant cell state underlies the behaviour of persister cells derived from a wide range of cancers and drug treatments. Consequently, we demonstrate that persister cells acquire a dependency on GPX4. Loss of GPX4 function results in selective persister cell ferroptotic death in vitro and prevents tumour relapse in mice. These findings suggest that targeting of GPX4 may represent a therapeutic strategy to prevent acquired drug resistance.

8 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYilong Zou
Yilong Zou
MPMichael J. Palte
Michael J. Palte
ADAmy A. Deik
Amy A. Deik
HLHaoxin Li
Haoxin Li
JEJohn K. Eaton
John K. Eaton
SSStuart L. Schreiber
Stuart L. Schreiber
Clear-cell carcinomas (CCCs) are a histological group of highly aggressive malignancies commonly originating in the kidney and ovary. CCCs are distinguished by aberrant lipid and glycogen accumulation and are refractory to a broad range of anti-cancer therapies. Here we identify an intrinsic vulnerability to ferroptosis associated with the unique metabolic state in CCCs. This vulnerability transcends lineage and genetic landscape, and can be exploited by inhibiting glutathione peroxidase 4 (GPX4) with small-molecules. Using CRISPR screening and lipidomic profiling, we identify the hypoxia-inducible factor (HIF) pathway as a driver of this vulnerability. In renal CCCs, HIF-2α selectively enriches polyunsaturated lipids, the rate-limiting substrates for lipid peroxidation, by activating the expression of hypoxia-inducible, lipid droplet-associated protein (HILPDA). Our study suggests targeting GPX4 as a therapeutic opportunity in CCCs, and highlights that therapeutic approaches can be identified on the basis of cell states manifested by morphological and metabolic features in hard-to-treat cancers.

16 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
YZYilong Zou
Yilong Zou
WHWhitney S. Henry
Whitney S. Henry
EREmily L. Ricq
Emily L. Ricq
EGEmily T. Graham
Emily T. Graham
VPVaishnavi V. Phadnis
Vaishnavi V. Phadnis
SSStuart L. Schreiber
Stuart L. Schreiber

17 February 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
YZYilong Zou
Yilong Zou
HLHaoxin Li
Haoxin Li
EGEmily T. Graham
Emily T. Graham
ADAmy A. Deik
Amy A. Deik
JEJohn K. Eaton
John K. Eaton
SSStuart L. Schreiber
Stuart L. Schreiber